MercadoLibre (MELI), the Brazilian e-commerce behemoth that’s not just commanding the online marketplace but is also bulldozing its way into fintech and beyond is often dubbed the “Amazon of Latin America,” but this comparison, while flattering, might be a disservice. It may also unfair to label it just a Brazilian company because it features in Argentina and Mexico too.
» Read more about: 1 Brazilian Stock To Buy and Hold for 10 Years »
Boasting an impressive 62% gain in its stock price this year, Atlassian has become the darling of investors with an affinity for enterprise software. The Ozzie company seems to be back in vogue, buoyed by rejuvenated revenue growth.
So, is there more juice to squeeze out of this tasty stock?
Which is more important to you, a steadily growing portfolio that spits out income regularly, or maximizing your returns?
Having both would be nice but sadly that’s not the way the market works typically. You can pick a more volatile stock that has lots of ups and downs, and can outperform, or you can pick a steady grower that spits out income regularly but doesn’t produce as high an overall return.
In a world drowning in data, Snowflake has been a lifeboat for businesses. Its cloud-based data warehousing capabilities allow organizations to manage a variety of data—structured, semi-structured, or unstructured—across different cloud services. Should a client wish to switch cloud providers, Snowflake’s service can facilitate that without a hitch.
Without Snowflake, companies would be at the mercy of cloud providers,
» Read more about: Is This Buffett Stock The Next BIG Thing? »
Dollar General has underperformed the market by 69% this year, posting a year-to-date loss of 53% but perhaps the decline has provided value investors with a new opportunity now that the price-to-earnings ratio is just 11.7x, almost half the multiple of the S&P 500.
It’s impossible to discuss Moderna without mentioning its COVID-19 vaccine, which propelled the stock to record highs in 2021 approaching $500 per share. However, slower sales caused the stock to plunge by almost 80%.
Second-quarter reports in 2023 show a net loss of $1.38 billion, a stark contrast to the net income of $5.4 billion in Q4 2021.
» Read more about: Spotlight: Time To Buy Vaccine Manufacturer Before Winter? »
It’s rare to find a stock offering a 9%+ yield that doesn’t have some murkiness under the hood, but is Medical Properties Trust (NYSE: MPW) that diamond in the rough?
We investigate whether this REIT that specializes in leasing healthcare facilities, a segment that has been traditionally regarded as recession-resistant, is worthy of a portfolio spot now.
» Read more about: Market Commentary: Time To Buy This 9.12% Yield Stock? »
The founder of Baron Capital, a firm with approximately $50 billion under management, believes that Tesla has the potential to quadruple in value over the next seven years.
Ron Baron isn’t just a voice in the wind, his fund has delivered an annualized return of 15.4% over the last 20 years, handily beating the S&P 500.
» Read more about: Market Commentary: Why Tesla Could 4x in the Next 7 Years »
If getting paid passively monthly sounds like something you’ve been looking for, Realty Income might be just the stock you’ve been looking for. From a single store 54 years ago, Realty Income is now a true behemoth that rewards investors seeking monthly income.
Crocs (NASDAQ:CROX) has been a roller-coaster of an investment, to say the least. From lows of $10 in 2020 to highs around $180 in 2021 and back under $50 again in 2022, the share price has bucked investors around like a wild bull at a county fair.
And despite falling far short of the market this year –
» Read more about: Market Commentary: 1 Growth Stock That Is Crushing Asia »
